

Day 1 Monday, October 28

17:00-19:30	Conference Registration
19:30	Welcome Drinks-Dinner at hotel

Each session consists of longer talks (15+5 for Q&A) and some short talks (8+2 Q&A), Please pay attention to the time allocated.

Day 2 Tuesday, October 29

07:30	Breakfast
09:00	Welcome Costas Koumenis, <i>UPenn</i>
09:05	Salutation and brief remarks Demetrios Skourides, <i>Chief Scientist for Research, Innovation and Technology/President of Research & Innovation Foundation (RIF)</i>
09:15	Salutation and brief remarks Andreas Hadjihambis, <i>Chair of the Cyprus Biological Society</i>
09:20-11:00	Session I Targeting aberrant metabolism in tumor-stroma interactions Chair: Costas Koumenis 09:20 Costas Lyssiotis, Univ. of Michigan Targeting PIKfyve-driven lipid homeostasis as a metabolic vulnerability in pancreatic cancer 09:40 Lauren Colbert, MDACC The Role of Lactic Acid Bacteria in the Tumor Microenvironment in Metabolic Rewiring and Therapeutic Response 10:00 Catherine Cook, Wake Forest Univ. Microbiome-derived metabolite interactions with host influence breast cancer risk and therapeutic outcomes 10:20 Thales Papayiannakopoulos, NYU Dissecting the crosstalk of nutrient sensing, stress response signaling and immune evasion 10:40 Marianne Koritzinsky, Univ. of Toronto Cysteamine dioxygenase (ADO) is needed in cancer cells to restrain proline metabolism and mitochondrial ROS production
11:00-11:30	Coffee Break - Discussions & Poster Viewing
11:30-14:20	Session II The immune landscape of tumors, cancer cell plasticity & immune evasion Chair: Sandra Ryeom 11:30 Rumela Chakrabarti, Univ. of Miami Overcoming immunotherapy resistance in Triple negative breast cancer 11:50 Malay Haldar, UPenn Function and regulation of a distinct subset of iron-rich macrophages in the tumor microenvironment 12:10 Viraj Sangvi, Columbia Univ. Understanding Immune Suppression in Over-nutrition-promoted Liver Cancer 12:30 Irfan Asangani, UPenn Leveraging Genome Instability to Transform Immune-Cold Prostate Cancer into an Immune-Responsive State 12:50 Rami Aqeilan, Cyprus Cancer Research Institute (CCRI) Mapping and Characterizing the Landscape of DNA Double Strand Breaks in the Human Genome 13:10 David Piwnica-Worms, MDACC Anti-Cancer Immune Activation with Beta-Radioligand Therapy and Selective Targeting of the 4Ig Isoform of B7-H3 13:30 Camilla Wolowczyk, NTNU A new role for CXCL3 in shaping the metastatic tumor microenvironment 13:40 Yuki Mochida, Inst of Sci, Tokyo Glucose-PEG modification of anti-PD-L1 antibodies for effective glioblastoma immunotherapy 13:50 David Soto-Pantoja, WFUSM Immunotherapeutic Potential of SIRPα Blockade in the Tumor Microenvironment of Triple-Negative Breast Cancer Brain Metastasis 14:00 Helen Piwnica-Worms, MDACC Fasting-mediated radioprotection
14:20	Lunch/informal discussions
19:00	Wine tasting and dinner at local taverna

07:30	Breakfast
08:30-10:20	<p>Session III Integrated Stress Response and Unfolded Stress Response Chair: Crystal Conn</p> <p>08:30 Rob Rottapel, <i>Univ. of Toronto</i> Stress Adaptation as an Emergent Vulnerability in Ovarian Cancer</p> <p>08:50 Kirk Staschke, <i>Indiana Univ.</i> GCN2 coordinates amino acid and purine metabolism to promote prostate cancer</p> <p>09:10 Xi Chen, <i>MDACC</i> Stress Management in Therapy-Resistant Cancers</p> <p>09:30 Dadi Jiang, <i>MDACC</i> The tumor microenvironment and the associated factors in mediating cellular sensitivity to ferroptosis</p> <p>09:50 Manon Nivet, <i>INSERM</i> A novel IRE1 target ITGA6 controls glioblastoma aggressiveness</p> <p>10:00 Nora Kiledjian, <i>UPenn</i> Deciphering the role of m6A in translation during an adaptive stress response</p> <p>10:10 Prithvi Sinha, <i>UPenn</i> Targeting ATF4/PERK-mediated dysfunction to improve $\gamma\delta$ T cell-based immunotherapy in glioblastoma</p>
10:20-11:00	Coffee Break-Discussions & Poster Viewing
11:00-13:15	<p>Session IV Brain & Neuroendocrine tumors: novel approaches for detection and treatment Chair: Maria Tsiarli</p> <p>11:00 Georgio Seano, <i>Institut Curie Paris</i> How surgical resection shapes glioblastoma microenvironment and promotes plasticity</p> <p>11:20 Costas Hadjipanayis, <i>Univ. Pittsburgh</i> 5-ALA-Mediated Photodynamic Therapy in Combination with MEK Inhibitors for the Treatment of H3K27-Mutated Diffuse Midline Glioma.</p> <p>11:40 Lenka Munoz, <i>Univ of Sydney</i> Target deconvolution strategies to delineate the mechanism of action of the KDM4 inhibitor QC6352 in glioblastoma</p> <p>12:00 Ivana Dokic, <i>Univ. of Heidelberg</i> Proton, Helium- and Carbon- Ion Radiotherapy: Impact on Tissue Microenvironment</p> <p>12:20 Yi Fan, <i>UPenn</i> FLASH-CAR therapy for brain tumors</p> <p>12:40 Diana Shi, <i>DFCI/Harvard</i> Identification of epigenetic regulators mediating sensitivity of IDH-mutant gliomas to replication stress</p> <p>12:50 Hiroaki Kinoh, <i>ICONM, Japan</i> Enhancing Chemo-Immunotherapy with Epirubicin Micelles and Anti-PD-1 Antibodies: Reprogramming the Tumor Microenvironment to Overcome Immune Checkpoint Inhibitor Resistance</p> <p>13:00 Mariam El-Ashmawy, <i>Columbia Univ.</i> Therapeutic approaches for wild-type KRAS amplified gastroesophageal cancer</p>
13:10	Short break
13:15-14:00	<p>Sponsor Presentations</p> <p>13:15 Marija Plodinec, <i>Artidis</i> Transforming cancer care: harnessing tissue mechanics for diagnostics and treatment optimization in solid tumors</p> <p>13:40 X-Strahl</p> <p>13:50 Raymed</p>
14:00-15:00	Lunch
15:30-22:30	Cultural Tour and Dinner/Informal Discussions at Local Tavern

07:30	Breakfast
08:00-10:15	<p>Session V Special Session: Dr. Amato Giaccia: The career of a Radiobiologist, Tumor Biologist and mentor Chair and introduction: Costas Koumenis and Albert Koong</p> <p>08:15 Amato Giaccia, Oxford Univ The role of hypoxia in promoting immune suppression</p> <p>08:50 Ester Hammond, Oxford Univ Physiologically relevant changes in redox lead to both replication and transcriptional stress</p> <p>09:10 Nic Denko, Ohio State Univ. Oxygen demand driven tumor hypoxia treated in mouse and human radiation protocols</p> <p>09:30 G-One Ahn, Seoul Natl. Univ. Tumor hypoxia and immune cells: to be or not to be</p> <p>09:55 Eujung Moon, Oxford Univ The Roles of Iron, Lipid Peroxidation, and Ferroptosis to unravel FLASH effect</p> <p>10:05 Nektarios Kostopoulos, UPenn Radiation-Induced Novel CAR T Cell Targets for pancreatic Adenocarcinoma</p>
10:15-10:45	Coffee Break-Discussions & Poster Viewing
10:45-13:45	<p>Session VI Cancer Radiotherapy: Recent advances with established paradigms and new technologies Chair: Erato Markidou</p> <p>10:45 Nicolaos Zamboglou, German Oncol. Centre, Cyprus Keynote lecture, Brachytherapy - Quo vadis</p> <p>11:20 James Metz, UPenn Proton Therapy and the promise of FLASH</p> <p>11:40 Julie Schwartz, Washington Univ. Radiation induced changes in the cervical cancer tumor immune microenvironment</p> <p>12:00 Ramesh Rengan, Univ. Washington Radiation and Immune Modulation in the Era of Precision Oncology</p> <p>12:20 Andrea Mairani, Heidelberg Using High-LET Particle Therapy to Overcome Biological Uncertainties</p> <p>12:40 Edgar Ben-Josef, UPenn A phase I dose escalation study of radiation and nab-paclitaxel (nab-p) in patients with unresectable and borderline resectable pancreatic cancer</p> <p>13:00 Constantinos Zamboglou, German Oncol Centre, Cyprus Where is the 'biology' in current prostate cancer radiotherapy: introducing Prostate-Specific Membrane Antigen (PSMA)</p> <p>13:15 Vedang Murthy, Tata Memorial Hospital Current updates in Radiotherapy for bladder cancer</p> <p>13:30 Dimitrios Vomvas, BOCOC SBRT-Transforming the future of radiation treatment for localized prostate cancer.</p>
13:45-15:00	Lunch
14:00	Optional - Trip to Latchi-Lunch & Boat Trip to "Blue Lagoon"
18:00	Dinner/Informal Discussions at Latchi

Day 5 Friday, November 1



07:30	Breakfast
08:30-10:40	Session VII Tumor hypoxia and the tumor stroma influence on growth and therapy response Chair: Ester Hammond 08:30 David Kirsch , <i>Univ. of Toronto/PMH</i> Crosstalk between tumor cells and the tumor microenvironment impact immunosurveillance and response to immunotherapy 08:50 Brad Wouters , <i>Univ of Toronto /PMH</i> Hypoxia drives spatially distinct epigenetic and transcriptional cell states in Glioblastoma 09:10 Serge Fuchs , <i>UPenn</i> Agonist-based approaches to normalizing the tumor microenvironment 09:30 Sheila Stewart , <i>Washington Univ.</i> Age Related Stromal Changes in Tumor Progression and Therapy-Induced Comorbidities 09:50 Qing Zhang , <i>UTSW</i> Identification of new therapeutic targets in tumor oxygen sensing signaling 10:10 Nicola Sibson , <i>Oxford Univ.</i> Selective opening the blood-brain barrier to facilitate detection and treatment of brain tumours when and where it matters 10:30 Omar Mian , <i>UW/Fred Hutch CC</i> Intratumoral androgen biosynthesis associated with 3 β -hydroxysteroid
10:40-11:20	Coffee Break-Discussions & Poster Viewing
11:20-13:30	Session V III Tumor physiology mechanics: new technologies for detection and treatment Chair: Diana Shi 11:20 Li Ma , <i>MDACC</i> New target against osteoporosis and bone metastasis 11:40 Ioannis Zervantonakis , <i>Univ. Pittsburgh</i> Collagen matrix remodeling by breast cancer cells promotes macrophage infiltration in a 3D microenvironment 12:00 Loukia Karacosta , <i>MDACC</i> Leveraging Single-Cell Proteomics for Mapping Therapy Resistant Phenotypes in the Tumor Microenvironment of Lung Cancer Liquid Biopsies 12:20 Fotios Mpekris , <i>Univ. of Cyprus</i> A synergistic approach for enhancing tumor perfusion and nanoimmunotherapy efficacy 12:40 Horacio Cabral , <i>Univ. of Tokyo</i> Nanomedicine Approaches Engineering the Tumor Microenvironment for Curative Interventions 13:00 Motohiro Kojima , <i>Univ. Tokyo</i> Pathological Role in the study of tumor microenvironment and cellular stress 13:10 Maria Kalli , <i>Univ. of Cyprus</i> Mechanical stress promotes autophagy activation to impair the efficacy of chemotherapy in pancreatic cancer 13:20 Sandra Ryeom , <i>Columbia Univ.</i> Closing remarks
13:30	Lunch/informal discussions
19:30	Farewell Gala Dinner at Coral Beach Hotel taverna

Day 6 Saturday, November 2

07:30	Breakfast
09:00	Departure

Antonia Charalambous, *Univ. of Cyprus*

Enhancing therapeutic efficacy of nano-immunotherapy in mouse sarcoma models through tumor microenvironment reprogramming

Saverio Charalambous, *Imperial College*

A novel explant-in-chip platform for intravascular delivery of exogenous agents ex vivo

Artemis Hadjigeorgiou, *Univ. of Thessaly, Hellenic Pasteur Institute*

A Deep Neural Network for Predicting Translation Initiation Start Positions

Isabella Hofer, *Institut Curie, Paris*

A subset of cancer associated fibroblasts increases the chemo-resistance of triple negative breast cancer by G0S2 upregulation

Kalisse Horne, *Drexel Univ.*

The Role of Timeless in Telomere Maintenance of ALT Cancer Cells

Gi-Sue Kang, *Seoul Natl Univ.*

Tirapazamine confers an abscopal effect when combined with anti-PD-1 antibodies through inducing hypoxia-specific cytosolic double-stranded DNA activating the systemic immune responses

Elisavet Krimitzia, *UPenn*

Stress-inducible hyaluronan deposition in tumor vasculature drives glioblastoma resistance to CAR T cell immunotherapy

Morgan McGrath, *UPenn*

The epitranscriptomics of cancer adaptivity: demystifying radiation-inducible mRNA pseudouridylation

Jayne Murray, *Children's Cancer Inst. Australia*

KDM4 inhibitor QC6352 in glioblastoma

Ioanna Papandreou, *Ohio State Univ.*

Liver lipid droplet regulators modify the tumor microenvironment in extrahepatic cancers

Erato Stylianou-Markidou, *Univ. of Cyprus*

Treatment Planning Approaches for Proton and Carbon FLASH

Ricardo Sainz, *ICR*

Radiotherapy induces aerobic glycolysis in myeloid populations in a murine mesothelioma model

Margie Sutton, *MDACC*

Disruption of the 4lg isoform of B7-H3 with Statins Reveals Tumor Intrinsic and Extrinsic Anti-tumor Efficacy

Kamila Součková, *Masaryk Univ.*

Using syngeneic mouse models to explore a potential approach to enhance the efficacy of immunotherapy in ovarian cancer and renal cell carcinoma

Stella Vasiliou, *Univ. of Toronto*

Determination of androgen-induced changes in the proteome of BT-474 breast cancer cells